Study Shows Significant Reductions In Blood Glucose With Investigational Compound Empagliflozin Used As Monotherapy In Adults With Type 2 Diabetes

Data presented at the American Diabetes Association 73rd Scientific Sessions® also showed reduction in body weight and systolic blood pressure in treated study subjects Boehringer Ingelheim and Eli Lilly and Company have announced results of a 24week Phase III clinical trial, which showed that treatment with the investigational compound empagliflozin* as monotherapy produced statistically significant reductions in HbA1c (average blood glucose) versus placebo, in patients with Type 2 Diabetes (T2D) who had not received any treatment for at least 12 weeks prior to randomisation...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Diabetes Source Type: news